SavedAdd your journal

Journals / Kafkas Journal of Medical Sciences / 2026 / Cilt: 11 Sayı: 2

Kemik Metastazı Tedavisinde Hedefleyici Radyoterapinin Eksternal Işın Radyoterapisi İle Eşzamanlı Kullanımı

Yasemin Benderli Cihan(Kayseri City Education and Research Hospital, Department of Radiation Oncology, Kayseri, Turkey)
Pages
350–352
Publication Date
2021-08-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Metastases to the bone are mostly caused by breast, prostate, lung, kidney and thyroid cancers

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In cancer patients, skeletal system metastases are the third most localized organ after lung and liver. 70% of bone metastases (BM) involve the axial skeleton and are mostly multiple.
📊
Key Findings & Data:The most common area is the vertebrae.
💡
Conclusion & Impact:Metastases to the bone are mostly caused by breast, prostate, lung, kidney and thyroid cancers
🔬Design:Editöre Mektup
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

In cancer patients, skeletal system metastases are the third most localized organ after lung and liver. 70% of bone metastases (BM) involve the axial skeleton and are mostly multiple. The most common area is the vertebrae. Metastases to the bone are mostly caused by breast, prostate, lung, kidney and thyroid cancers

🔖

Cite This Article

Cihan, Y. B. (2021). Kemik Metastazı Tedavisinde Hedefleyici Radyoterapinin Eksternal Işın Radyoterapisi İle Eşzamanlı Kullanımı. Kafkas Journal of Medical Sciences, Cilt: 11 Sayı: 2, 350–352. https://ajindex.com/articles/1631749

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. CihanYB, Sarıgöz T, Arslan A. Role of season in overall survival of patients with bone metastasis undergoing radiotherapy.Transl Cancer Res 2016;5(1):85-88.
  2. James N, Pirrie S, Pope A, Barton D, Andronis L, Goranitis I, et al. TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer. Health Technol Assess. 2016 Jul;20(53):1-288. doi: 10.3310/hta20530.PMID: 27434595 Clinical Trial.
  3. Hicsonmez A, Kucuk ON, Andrieu MN, Guney Y, Ibis E. Role of Radionuclide Therapy as Adjuvant to Palliative External Beam Radiotherapy for Painful Multiple Skeletal Metastasis. World J Oncol. 2010 Aug;1(4):158-166. doi: 10.4021/wjon235w. Epub 2010 Aug 29.PMID: 29147199.
  4. Heianna J, Toita T, Endo W, Kasuya G, Ariga T, Hashimoto S, et al. Concurrent use of strontium-89 with external beam radiotherapy for multiple bone metastases: early experience. Ann Nucl Med. 2015 Dec;29(10):848-53. doi: 10.1007/s12149-015-1010-6. Epub 2015 Aug 13.PMID:26266885.
  5. Liepe K, Franke WG, Kropp J, Koch R, Runge R, Hliscs R. Comparison of rhenium-188, rhenium-186-HEDP and strontium-89 in palliation of painful bone metastases]. Nuklearmedizin. 2000 Sep;39(6):146-51.PMID: 11057405 Clinical Trial. German.
  6. Heron DE, Brufsky A, Beriwal S, Kurman M. Myelotoxicity of samarium Sm 153 lexidronam in patients receiving prior treatment with chemotherapy or radiotherapy. Ann Oncol. 2008 Sep;19(9):1639-43. doi: 10.1093/annonc/mdn178. Epub 2008 May 7.PMID:18467311.
  7. Blitzer PH. Reanalysis Of The RTOG Study Of The Palliation Of Symtomatic Osseous Metastasis. Cancer, 1985;55(7):1468-72
  8. Sadremomtaz A, Masoumi M. An assessment of bone-seeking radionuclides for palliation of metastatic bone pain in a vertebral model. Ann Nucl Med. 2019 Apr;33(4):252-264. doi: 10.1007/s12149-019-01329-w. Epub 2019 Jan 18.PMID: 30659480.
  9. Kraeber-Bodere F, Campion L, Rousseau C, Rousseau C, Bourdin S, Chatal JF, et al. Treatment Of Bone Metastases Of Prostate Cancer With Strontium-89 Chloride: Efficacy İn Relation To The Degree Of Bone İnvolvement. Eur J Nucl Med, 2000;27:1487-93.
  10. Ayati N, Aryana K, Jalilian A, Hoseinnejad T, Samani AB, Ayati Z, et al. Treatment efficacy of (153)Sm-EDTMP for painful bone metastasis. Asia Ocean J Nucl Med Biol. 2013 Spring;1(1):27-31. doi:10.7508/aojnmb.2013.01.006.PMID:27408839.
  11. Paravati AJ, Russo AL, Aitken C. Adverse events in the long-term follow-up of patients treated with samarium Sm 153 lexidronam for osseous metastases. Int J Radiat Oncol Biol Phys. 2011 Oct 1;81(2):506-10. doi: 10.1016/j.ijrobp.2010.05.066. Epub 2010 Oct 1.PMID: 20888141.
  12. Oosterhof GO, Roberts JT, de Reijke TM, Engelholm SA, Horenblas S, Maase HVD et al. Strontium (89) Chlorid Eversus Palliative Local Field Radiotheraphy İn Patients With Hormonal Escaped Prostate Cancer; A Phase III Study Of The European Organisation For Research And Treatment Of Cancer, Genitourinary group. Eur Urol, 2003;44:519-26.
  13. Buchali K, Correns HJ, Schuerer M, Lips H, Sydow K. Results Of A Duble Blind Study Of Strontium-89 Theraphy Of Skeletal Metastases Of Prostatic Carcinoma. Eur J Nucl Med, 1988;14:349-51.
  14. Porter AT, McEwan AJ. Strontium-89 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer: results of a randomized controlled trial. Semin Oncol. 1993;20(3 Suppl 2):38–43.
  15. Porter AT, McEwan AJ, Powe JE, Reid R, McGowan DG, Lukka H et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 1993;25(5):805–813. doi: 10.1016/0360-3016(93)90309-J.